Renate Haidinger1, Ingo Bauerfeind2. 1. Brustkrebs Deutschland e.V./German Breast Cancer Association, Hohenbrunn. 2. Breast Center, Department of Obstetrics and Gynecology, Landshut Hospital, Landshut, Germany.
Abstract
BACKGROUND: Chronic treatment sequelae may substantially reduce the long-term quality of life in breast cancer survivors. METHODS: We report a comprehensive Web-based survey on the presence of long-term side effects of adjuvant anti-breast cancer therapy in 1,506 patients who had been diagnosed with primary breast cancer at least 1 year before. RESULTS: Fatigue, depression, depressive mood, concentration deficit, pain, changes of mucosa and skin appendages, as well as symptoms of peripheral neuropathy were the most prevalent reported complaints. Chemotherapies - taxane-based regimens in particular - were associated with increased rates of long-term symptoms, including persistent peripheral neuropathy. Overall, the data show a substantial prevalence of a wide variety of potentially treatment-associated symptoms over a protracted time frame after the diagnosis of breast cancer. The burden of symptoms was high for fatigue, depression, sleep disturbances, pain, and peripheral neuropathic symptoms. CONCLUSION: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence.
BACKGROUND: Chronic treatment sequelae may substantially reduce the long-term quality of life in breast cancer survivors. METHODS: We report a comprehensive Web-based survey on the presence of long-term side effects of adjuvant anti-breast cancer therapy in 1,506 patients who had been diagnosed with primary breast cancer at least 1 year before. RESULTS: Fatigue, depression, depressive mood, concentration deficit, pain, changes of mucosa and skin appendages, as well as symptoms of peripheral neuropathy were the most prevalent reported complaints. Chemotherapies - taxane-based regimens in particular - were associated with increased rates of long-term symptoms, including persistent peripheral neuropathy. Overall, the data show a substantial prevalence of a wide variety of potentially treatment-associated symptoms over a protracted time frame after the diagnosis of breast cancer. The burden of symptoms was high for fatigue, depression, sleep disturbances, pain, and peripheral neuropathic symptoms. CONCLUSION: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence.
Authors: G Murtagh; T Lyons; E O'Connell; J Ballot; L Geraghty; D Fennelly; G Gullo; M Ledwidge; J Crown; J Gallagher; C Watson; K M McDonald; J M Walshe Journal: Breast Cancer Res Treat Date: 2016-04-09 Impact factor: 4.872
Authors: Mandana Kamgar; Mark K Greenwald; Hadeel Assad; Theresa A Hastert; Eric M McLaughlin; Kerryn W Reding; Electra D Paskett; Jennifer W Bea; Aladdin H Shadyab; Marian L Neuhouser; Rami Nassir; Tracy E Crane; Kalyan Sreeram; Michael S Simon Journal: Cancer Med Date: 2021-08-14 Impact factor: 4.452